News in brief: CAR T therapy for indolent lymphomas; Dabigatran resistant to reversal agent; DLBCL trial criteria too restrictive

CAR T therapy offers promising results in indolent lymphomas The CAR T-cell therapy axicabtagene ciloleucel, or axi-cel, yielded high response rates and was well tolerated in a phase 2 study of patients with relapsed/refractory indolent non-Hodgkin lymphoma. Among a total of 104 patients, the overall response rate to the therapy was 92%, and the complete ...

Already a member?

Login to keep reading.

© 2021 the limbic